multilang-release
Montrouge, France, June 26, 2020
DBV Technologies Provides Operational and Business Update
BLA review of Viaskin Peanut for the treatment of peanut allergy in children ages 4-11 years ongoing
Company to immediately initiate restructuring plan to extend cash runway while awaiting FDA clarity
EPITOPE Phase III trial in toddlers ages 1-3 years ongoing; treatment benefit observed in Part A analysis
DBV Technologies (the Company) (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that given the Company has not yet received an update from the U.S. Food and Drug Administration (FDA) regarding it…
Read the full article at: https://www.globenewswire.com/news-release/2020/06/26/2053852/0/en/DBV-Technologies-Provides-Operational-and-Business-Update.html